These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Depo-Provera: costs eat up clinic contraceptive budgets.
    Journal: Contracept Technol Update; 1999 Jan; 20(1):1-3. PubMed ID: 12349019.
    Abstract:
    Manufactured by Pharmacia and Upjohn, Depo-Provera is the only injectable method of contraception available in the US. It was first introduced to the US in 1993, and first listed as a contraceptive method in the National Survey of Family Growth in 1995. Since 1993, Depo-Provera has become increasingly popular among female adolescents, who have switched from oral contraceptives (OCs) to the injectable method. For example, 17% of adolescent clients chose the method in 1997, jumping from an 11% increase in 1996. In 1995, the first year in which the use of Depo-Provera was tracked nationally, among sexually active, contracepting women, 19% of non-Hispanic Blacks and 10% of White and Hispanic adolescents reported using Depo-Provera as their first choice contraceptive method. This uptake in demand for Depo-Provera is straining and even overwhelming the budgets of many publicly funded family planning and reproductive health clinics. Pharmacia and Upjohn offers volume discounts on the purchase of Depo-Provera, but clinics, which already enjoy significant discounts on OCs, still argue that the costs of Depo-Provera are beyond their funding capacities. Depending upon the negotiated price, OCs may cost a clinic $2 per cycle, for an annual per patient cost of $24. Depo-Provera, however, may cost a clinic $15 per quarterly shot, for an annual per patient cost of $60.
    [Abstract] [Full Text] [Related] [New Search]